Zealand Pharma A/S

ZEAL

DK0060257814

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2026-06-12 am EDT			5-day change	1st Jan Change
295.80 ^DKK	+0.51%		-9.35%	-36.58%

Jun. 12	After Euphoria, a Traffic Jam on the Multi-Billion Dollar Kilo-Highway
Jun. 11	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE

Goldman Sachs trims Zealand Pharma price target to DKK 471 (491), reiterates Buy - BN

Published on 05/08/2026 at 01:13 am EDT

Finwire - Translated by Marketscreener - See original

ZEALAND PHARMA A/S

+0.51%

Goldman Sachs has lowered its price target for Zealand Pharma to DKK 471 from DKK 491, while maintaining its Buy rating - BN

Latest news about Zealand Pharma A/S

Jun. 12	After Euphoria, a Traffic Jam on the Multi-Billion Dollar Kilo-Highway
Jun. 11	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
Jun. 11	Wolfe Downgrades Zealand Pharma Following Weak Tolerability Data for Obesity Drug	FW
Jun. 10	Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon	RE
Jun. 10	DNB Carnegie trims Zealand Pharma price target to DKK 425 (440), reiterates Buy	FW
Jun. 09	Zealand Pharma A/S Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 01:20 PM
Jun. 09	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
Jun. 09	U.S. Futures Rise, European Stocks Mixed	DJ
Jun. 08	Major European indices flat - Zealand Pharma plunges	FW
Jun. 08	Markets Ask AI for Receipts
Jun. 08	Zealand Pharma plunges following side effects in obesity drug trial	FW
Jun. 08	U.S. Futures Mixed, European Stocks Fall	DJ
Jun. 08	Zealand Pharma shares drop 25% after a quarter of patients quit obesity drug trial	RE
Jun. 08	Chips take a pounding
Jun. 08	Zealand Pharma partner reports robust Phase 3 obesity data	FW

Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2025, the Group had a portfolio of 8 products in clinical development (including 3 in phase III, 3 in phase II and 2 in phase I), and 1 product in preclinical development.

Employees

544

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company